NephroGenex loses $1.7 million in Q1

Posted by John Murawski on May 14, 2014 

Triangle drug developer NephroGenex reported late Wednesday that it lost $1.7 million, nearly four times more than its quarterly loss a year earlier, as the company increases spending to try and win regulatory approval for its products.

NephroGenex said it “made significant progress in the first quarter,” including a February IPO that raised $37.2 million and netted the company $33.4 million after expenses.

This year the 9-year-old, 7-employee company plans to begin a Phase 3 human trial of Pyridorin and initiate other regulatory filings and programs for its treatments for kidney disease. Pyridorin is an experimental treatment designed to slow the progression of diabetic nephropathy, a chronic, degenerative disease of the kidneys caused by diabetes.

The $1.7 million loss compares to a loss of $473,824 a year earlier. Research and development expenses increased to $500,000 from $300,000. General and administrative costs grew to $1 million from $100,000 as a result of new hires, increased costs for director-and-officer liability insurance, and increased costs related to running a publicly traded company.

The company’s shares have slipped since they began trading at $12 in February. The stock closed Wednesday at $5.28, down 39 cents.

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service